HC Wainwright Reaffirms Buy Rating for Talphera (NASDAQ:TLPH)

Talphera (NASDAQ:TLPH)‘s stock had its “buy” rating reiterated by investment analysts at HC Wainwright in a note issued to investors on Tuesday,Benzinga reports. They presently have a $6.00 price objective on the stock.

Several other equities research analysts also recently commented on the stock. RODMAN&RENSHAW raised shares of Talphera to a “strong-buy” rating in a report on Tuesday, January 28th. Rodman & Renshaw assumed coverage on shares of Talphera in a research note on Tuesday, January 28th. They set a “buy” rating and a $4.00 price target on the stock.

Talphera Stock Performance

TLPH opened at $0.58 on Tuesday. Talphera has a fifty-two week low of $0.45 and a fifty-two week high of $1.27. The firm has a 50-day moving average of $0.60 and a 200 day moving average of $0.71. The firm has a market cap of $9.93 million, a P/E ratio of -0.84 and a beta of 0.20.

Talphera (NASDAQ:TLPH) last issued its quarterly earnings results on Monday, March 31st. The company reported ($0.07) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.21) by $0.14. Equities research analysts predict that Talphera will post -0.64 earnings per share for the current fiscal year.

Talphera Company Profile

Talphera, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. Its lead product candidate is Niyad, a lyophilized formulation of nafamostat, which is under an investigational device exemption as an anticoagulant for the extracorporeal circuit.